» Articles » PMID: 30854051

DW-MRI for Esophageal Squamous Cell Carcinoma, Correlations Between ADC Values with Histologic Differentiation and VEGF Expression: A Retrospective Study

Overview
Journal Oncol Lett
Specialty Oncology
Date 2019 Mar 12
PMID 30854051
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to assess the correlations between diffusion-weighted magnetic resonance imaging (DW-MRI) features with the histologic differentiation and the expression of vascular endothelial growth factor (VEGF) in esophageal squamous cell carcinoma (ESCC). A total of 52 patients with ESCC included in the present study received radiotherapy, and all patients underwent contrast enhanced MRI and DW-MRI prior to and following radiotherapy. The diffusion sensitivity coefficient ( value) was set as 800 s/mm. Apparent diffusion coefficient (ADC) values were automatically computed. VEGF expression was evaluated by immunohistochemical staining. The results demonstrated that the pathological grading of ESCC was positively correlated with ADC values (=0.635, P=0.0007), and the VEGF expression was inversely correlated with ADC values (=-0.321, P=0.008). However, no correlation was identified between the pathological grading and the VEGF expression (=0.178, P=0.284). All patients were categorized as complete response (CR) or partial response (PR) and the ADC values were increased significantly following radiotherapy. The mean ADC values in the CR group were higher than the PR group prior to radiotherapy (=5.156, P=0.0004). Therefore, we concluded that the DWI with ADC value measurement may represent the grade of tumor histologic differentiation and the degree of VEGF expression, and may also serve as a useful marker to predict radiotherapy and anti-VEGF response in ESCC. ADC value may be a substitution for assessing tumor angiogenesis and novel prognostic factor and contribute to the treatment of ESCC.

Citing Articles

Novel Advances in Qualitative Diagnostic Imaging for Decision Making in Multidisciplinary Treatment for Advanced Esophageal Cancer.

Okazumi S, Ohira G, Hayano K, Aoyagi T, Imanishi S, Matsubara H J Clin Med. 2024; 13(2).

PMID: 38276137 PMC: 10816440. DOI: 10.3390/jcm13020632.


A correlative study between IVIM-DWI parameters and VEGF and MMPs expression in hepatocellular carcinoma.

Yang C, Wei X, Zheng J, Tao Y, Gong X, Li L Quant Imaging Med Surg. 2023; 13(3):1887-1898.

PMID: 36915336 PMC: 10006110. DOI: 10.21037/qims-22-271.


Development and Validation of the Predictive Model for Esophageal Squamous Cell Carcinoma Differentiation Degree.

Wang Y, Yang Y, Sun J, Wang L, Song X, Zhao X Front Genet. 2020; 11:595638.

PMID: 33193745 PMC: 7645151. DOI: 10.3389/fgene.2020.595638.


Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors-A Systematic Review and Meta-Analysis.

Meyer H, Wienke A, Surov A Diagnostics (Basel). 2019; 9(4).

PMID: 31547581 PMC: 6963772. DOI: 10.3390/diagnostics9040126.


Imaging biomarkers for the treatment of esophageal cancer.

Hayano K, Ohira G, Hirata A, Aoyagi T, Imanishi S, Tochigi T World J Gastroenterol. 2019; 25(24):3021-3029.

PMID: 31293338 PMC: 6603816. DOI: 10.3748/wjg.v25.i24.3021.

References
1.
Baur A, Dietrich O, Reiser M . Diffusion-weighted imaging of bone marrow: current status. Eur Radiol. 2003; 13(7):1699-708. DOI: 10.1007/s00330-003-1873-0. View

2.
Rafii S, Lyden D . Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003; 9(6):702-12. DOI: 10.1038/nm0603-702. View

3.
Kim C, Park B, Lee H, Kim S, Kim E . MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol. 2008; 190(5):1180-6. DOI: 10.2214/AJR.07.2924. View

4.
Leber M, Efferth T . Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 2009; 34(4):881-95. DOI: 10.3892/ijo_00000214. View

5.
Teng L, Jin K, He K, Zhang J, Wang H, Cao J . Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010; 73(9):449-56. DOI: 10.1016/S1726-4901(10)70097-6. View